Back to top

Image: Bigstock

Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate

Read MoreHide Full Article

Shares of Celyad Oncology SA ((CYAD - Free Report) ) went up about 10.8% after it announced that the FDA cleared the investigational new drug (IND) application for its short hairpin RNA (shRNA)-based allogeneic candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma (r/r MM). The phase I study for the candidate is expected to begin by the end of 2020. CYAD-211 targets B-cell maturation antigen (BCMA) protein/antigen and represents the company’s lead off-the-shelf product candidate based on differentiated non-gene edited allogeneic technology

However, shares of the company have gained 5.1% compared with the industry’s growth of 6.4%.

The company is developing several allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors.

There are a number of big pharmaceutical companies that are also developing CAR T Therapies. One such company is Gilead Sciences Inc. (GILD - Free Report) . Gilead is seeking approval for its CAR T therapy candidate, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Novartis’ (NVS - Free Report) CAR T therapy drug, Kymriah, is also approved in the United States for B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.


Zacks Rank and Another Stock to Consider

Celyad currently carries a Zacks Rank #4 (Sell). A top-ranked stock in the biotech sector is Emergent Biosolutions Inc. (EBS - Free Report) , carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Emergent’s earnings per share estimates have increased from $3.18 to $4.03 for 2020 and from $3.32 to $4.31 for 2021 in the past 60 days.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Gilead Sciences, Inc. (GILD) - free report >>

Novartis AG (NVS) - free report >>

Emergent Biosolutions Inc. (EBS) - free report >>

Celyad SA (CYAD) - free report >>